Okey Stephanie 4

What Happened Stephanie Okey, a director of Crinetics Pharmaceuticals (CRNX), sold a total of 6,900 shares in two open-market transactions on June 17, 2026. She sold 6,292 shares at a volume-weighted average price (VWAP) of $35.62 for proceeds of $224,121, and 608 shares at a VWAP of $36.22 for proceeds of $22,022 — total proceeds ≈ $246,143. These sales were reported on Form 4 filed June 18, 2026.

Key Details

• Transaction date: June 17, 2026; Form 4 filed: June 18, 2026 (timely filing).
• Trades: two open-market sales (reporting code S).
  • 6,292 shares at VWAP $35.62 (range $35.19–$36.06) — $224,121 (F2).
  • 608 shares at VWAP $36.22 (range $36.19–$36.29) — $22,022 (F3).
• Total shares sold: 6,900; total proceeds ≈ $246,143.
• Footnote: Sales were effected automatically under a Rule 10b5-1 trading plan adopted Nov 19, 2025 (F1).
• Shares owned after the transaction: not specified in the provided filing; consult the full Form 4 or issuer for updated holdings.

Context These were sales, not purchases; sales executed under a pre-established 10b5-1 plan are typically routine and do not by themselves indicate a change in the insider's view of the company. No option exercises, gifts, or tax-withholding events were reported in this filing.